|
The Changing Face of ADHD: Addressing
Changing Symptoms, Adjusting Treatment Management
An Internet CME Newsletter
Vol 2 No 1, April 2007
WELCOME
Attention-deficit/hyperactivity disorder (ADHD) is a serious health care
concern that affects 6% to 8% of school-aged children and approximately 4%
of adults. Symptoms may improve with age, but for most patients diagnosed
as children, impairment persists into adolescence and adulthood. ADHD has
been linked to increased risk for comorbidities, including behavioral,
mood, anxiety, and substance use disorders. ADHD has also been associated
with impairments in the social, academic, and occupational domains.
All adolescents must
learn to handle the increased responsibilities and decreased adult
supervision characteristic of emerging adulthood. But for patients with
ADHD, this transition can be especially difficult. Faced with heavier
demands in school and at work and with the greater availability of drugs
and alcohol, these patients may find the impairments associated with ADHD
especially burdensome. Adjusting their medication dosages or adding
adjunctive psychotherapy may be helpful during this difficult transition.
This newsletter,
The Changing Face of ADHD: Addressing Changing Symptoms, Adjusting
Treatment Management, covers the changing symptomatology in persistent
ADHD and briefly discusses treatment options. The second newsletter in
this series will focus more on the available treatment options, including
proper titration and dosage of pharmacotherapies, as well as on safety
concerns, in adolescents and young adults.
We hope this
newsletter helps you manage your patients who are progressing through
adolescence. We invite you to send us your feedback.
Sincerely,
Timothy E. Wilens, MD
Director, Substance Abuse Services
Pediatric Psychopharmacology Research Unit
Massachusetts General Hospital
Associate Professor, Psychiatry
Harvard Medical School
Boston, Massachusetts
Method of Participation
Read this newsletter, complete
the CME Activity Posttest and Evaluation/Request for Credit Form online
and receive your certificate immediately. This activity is provided free
of charge to participants.
Intended Audience
Psychiatrists and other
physicians who treat patients with ADHD
Effective Dates
April 2007 through March 31,
2008
Accreditation/Designation of Credit
Statements
Veritas Institute for Medical
Education, Inc. is accredited by the Accreditation Council for Continuing
Medical Education to provide continuing medical education for physicians.
Veritas Institute
for Medical Education, Inc. designates this educational activity for a
maximum of 1 AMA PRA Category 1 CreditTM.
Physicians should only claim credit commensurate with the extent of their
participation in the activity.
Sponsorship and
Support
Sponsored by Veritas Institute
for Medical Education, Inc.
Supported by an educational grant from McNeil Pediatrics Division of
McNeil-PPC, Inc. administered by Ortho-McNeil Janssen Scientific Affairs,
LLC.
Financial
Disclosure Statements
In accordance with the ACCME’s
Standards for Commercial Support, all CME providers are required to
disclose to the activity audience the relevant financial relationships of
the planners, teachers, and authors involved in the development of CME
content. An individual has a relevant financial relationship if he or she
has a financial relationship in any amount occurring in the last 12 months
with a commercial interest whose products or services are discussed in the
CME activity content over which the individual has control. Disclosures
are as follows:
Timothy E. Wilens,
MD:
Abbott Laboratories (grant support,
speakers bureau, consultant), Cephalon Inc (grant support, speakers
bureau, consultant), Eli Lilly and Company (grant support, speakers
bureau, consultant), Janssen Pharmaceutica Products LP (consultant),
National Institute of Mental Health (consultant), National Institute on
Drug Abuse (grant support, speakers bureau, consultant), Novartis
Pharmaceuticals Corporation (speakers bureau, consultant), Neurosearch
(grant support), Ortho-McNeil Pharmaceutical Inc (grant support, speakers
bureau, consultant), Pfizer Inc (consultant), Shire (grant support,
speakers bureau, consultant).
The staff of Veritas
Institute for Medical Education, Inc. has nothing to disclose.
Unlabeled Use
Disclosure Statement
Participants are advised that
this CME activity will contain references to
unlabeled/unapproved/investigational uses of drugs to treat ADHD.
Disclaimer
The opinions expressed in this
activity are those of the faculty and do not necessarily reflect those of
Veritas Institute for Medical Education, Inc. or McNeil Pediatrics
Division of McNeil-PPC, Inc. administered by Ortho-McNeil Janssen
Scientific Affairs, LLC. Please consult the appropriate package insert
for full prescribing information on all drug therapies discussed.
Copyright © 2007
Veritas Institute for Medical Education, Inc. All rights reserved.
Terms and Conditions |
Privacy Policy
Editor
Timothy E. Wilens, MD
Director, Substance Abuse Services
Pediatric Psychopharmacology Research Unit
Massachusetts General Hospital
Associate Professor, Psychiatry
Harvard Medical School
Boston, Massachusetts
LEARNING OBJECTIVES
1. You will be better able to
recognize age-related changes in ADHD symptomatology, as well as the
presence of psychiatric comorbidities, when diagnosing and treating ADHD
in adolescents and young adults.
2. Using
evidence-based methods, you will be able to select and titrate ADHD
medications to improve academic, social, and occupational performance in
your adolescent and young adult patients.
|